Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Pixium Vision S.A. logo — Innovating at the frontier of neuroscience : brain machine i...

Pixium Vision S.A.

Innovating at the frontier of neuroscience : brain machine interfacing the Eye and the Brain - from photons to neurons !

Founded 2011 France France 13 employees Post-IPO Equity Total: $33.30M Health Care, Information Technology +1

General Information

Company Name Pixium Vision S.A.
Founded Year 2011
Location France France
Employees 13
Industries Health Care, Information Technology, Medical Devices
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Pixium Vision S.A.. To contact Pixium Vision S.A., visit pixium-vision.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Pixium Vision S.A. compare?

A PDF of Pixium Vision S.A. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Pixium Vision S.A. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Pixium Vision S.A.

Pixium Vision S.A. is a pioneer in the field of neuroscience, focusing on brain-machine interfacing to restore vision for individuals with retinal degeneration. The company has developed two innovative Bionic Vision Systems, PRIMA (Subretinal) and IRIS®II (Epiretinal), aimed at compensating for vision loss and blindness from conditions such as Dry Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP). These systems leverage state-of-the-art biomedical and bioelectronic technologies, along with smart bio-inspired algorithms and AI, to enable minimal invasive retinal surgery and provide blind individuals with a form of prosthetic bionic vision. Founded in 2011, Pixium Vision has made significant strides in the field of neuromodulation technology, aiming to restore a form of prosthetic vision. The company went public on the Euronext Paris stock exchange in 2014 and has continued to collaborate with renowned scientific and clinical partners, including Institut de la Vision Paris, Stanford University California, Moorfields Eye Hospital London, and Institute of Ocular Microsurgery (IMO) Barcelona. Notably, the company received a €7.30M post-IPO equity investment on 15 July 2020 from Bpifrance and Sofinnova Partners, demonstrating confidence in its innovative vision restoration technology. With its groundbreaking approach and strategic collaborations, Pixium Vision is poised to make a significant impact in the healthcare and medical devices industries, particularly for individuals with vision loss.

Business keywords: Bionic Vision Systems, Neuroscience, Neuromodulation, Bioelectronics, Artificial Vision, Retinal Implant Systems, Neuro-Ophthalmology, Bioelectronic Technologies, Digital Medicine, Retinitis Pigmentosa, Age-Related Macular Degeneration (AMD), Sensory Neuromodulation, Neurobiological Research, Bioelectronic Medicine, Neuro-Ophthalmic Implants

Services & Products

Development and commercialization of medical devices for ophthalmic applications

Target Customers

Healthcare institutions ophthalmologists patients with macular degeneration

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €7.30M 2
Bpifrance Sofinnova Partners
Bpifrance, Sofinnova Partners
15 Jul 2020
Post IPO Debt €11.00M 1
Kreos Capital
Kreos Capital
29 Sep 2016
Series A €15.00M 5
Bpifrance Omnes Capital Sofinnova Partners
Bpifrance, Omnes Capital +3
25 Nov 2013
Venture Round Undisclosed 1
AGORANOV
AGORANOV
01 Jan 2012

Pixium Vision S.A. Alternatives & Competitors

Pixium Vision S.A. vs
Bionic Vision Technologies
Bionic Vision Technologies Australia

Restoring a sense of vision to the blind.

Series A
6 employees
Biotechnology, Health Care

FAQ About Pixium Vision S.A.

Innovating at the frontier of neuroscience : brain machine interfacing the Eye and the Brain - from photons to neurons !
Pixium Vision S.A. was founded in 2011.
Pixium Vision S.A. is headquartered in France.
Pixium Vision S.A. operates in Health Care, Information Technology and Medical Devices. Its work centres on Bionic Vision Systems, Neuroscience, Neuromodulation and Bioelectronics. Its customers include Healthcare institutions, ophthalmologists and patients with macular degeneration.
Pixium Vision S.A. has approximately 13 employees.
Pixium Vision S.A. has completed 4 funding rounds, raising a total of $33.30M. The latest funding stage is Post-IPO Equity.
Pixium Vision S.A. offers: Development and commercialization of medical devices for ophthalmic applications.
Top alternatives and competitors to Pixium Vision S.A. include Bionic Vision Technologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pixium Vision S.A. and Bionic Vision Technologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Pixium Vision S.A., https://bouncewatch.com/company/pixium-vision-sa, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout